CN102172261A - Composition for constructing animal model of diabetes mellitus type II - Google Patents
Composition for constructing animal model of diabetes mellitus type II Download PDFInfo
- Publication number
- CN102172261A CN102172261A CN2011100552130A CN201110055213A CN102172261A CN 102172261 A CN102172261 A CN 102172261A CN 2011100552130 A CN2011100552130 A CN 2011100552130A CN 201110055213 A CN201110055213 A CN 201110055213A CN 102172261 A CN102172261 A CN 102172261A
- Authority
- CN
- China
- Prior art keywords
- composition
- cla
- animal model
- type
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a composition for constructing an animal model of diabetes mellitus type II and application of the composition to preparing feeds or drugs for constructing the animal model of the diabetes mellitus type II, wherein the composition comprises a conjugated linoleic acid mixture of which the weight percentage is more than 0.1% relative to the composition; and the animal model of the diabetes mellitus type II is prepared by feeding the composition to the mouse. Because the conjugated linoleic acid mixture or a single conjugated linoleic acid monomer is adopted as an inducer and the mouse is adopted as the animal protomodel, compared with a traditional chemical drug or diet induced animal model of the diabetes mellitus type II, the composition provided by the invention has the advantages of low price, convenience and easiness for raw material obtaining; and because the model establishing time is 4-6 weeks, the period is short, the formed model is characterized by hyperglycemia, high insulin level and in-vivo insulin resistance, the composition accords with basic characteristics of the diabetes mellitus type II and is an ideal composition for constructing the animal model of the diabetes mellitus type II.
Description
Technical field
The present invention relates to a kind of composition, relate in particular to a kind of composition that makes up the type ii diabetes animal model.
Background technology
Chinese residents nutrition survey result showed in 2002, and China 18 years old and above resident's diabetes prevalence are 2.6%, and the IFG rate is 1.9%.Estimate the existing number of patients more than 2,000 ten thousand of national diabetes, other has nearly 2,000 ten thousand people's IFGs.The city illness rate is apparently higher than the rural area, and a class rural area is apparently higher than four class rural areas.Compare with diabetes sample investigation data in 1996, the big city more than 20 years old diabetes prevalence by 4.6% rise to 6.4%, small and medium-sized cities rise to 3.9% by 3.4%.Type ii diabetes also is adult's morbidity type diabetes, how falls ill after 35-40 year, accounts for the diabetic more than 90%, and along with growth in the living standard, the incidence of disease among the children also has trend of rising in recent years.The ability that produces insulin in the type ii diabetes patient body is not to completely lose, insulin even generation are too much in the patient's body that has, but the action effect of insulin is had a greatly reduced quality, so the essential characteristic of type ii diabetes is that blood sugar and insulin raise simultaneously, has insulin resistance in the body.
The type ii diabetes animal model is that research type ii diabetes cause and exploitation related drugs become the requisite animal model of branch with health food.Model comparatively commonly used at present can be divided into two classes, and a class is a heredity type ii diabetes animal model, and another kind of is chemicals or diet induced type ii diabetes animal model.Heredity type ii diabetes animal price general charged costliness, and can not well reflect the type ii diabetes that the mankind cause owing to environmental factors such as dietary structure are unreasonable, so model commonly used at present mostly is chemicals or diet induced type ii diabetes model.Chemicals inductivity type ii diabetes model have that required chemicals costs an arm and a leg, dosage is difficult to control, become problems such as mould instability, and there is long, problem such as blood sugar rising amplitude is little of modeling time in diet induced type ii diabetes model, therefore, this research field is badly in need of a kind of cheap, becomes the effective novel I type i diabetes animal model of mould.
Summary of the invention
Technical problem to be solved by this invention is to be to provide a kind of composition and new method, is used to make up the type ii diabetes animal model, to remedy the above-mentioned deficiency of prior art.
The invention provides a kind of composition and be used for making up the application of the feed or the medicine of type ii diabetes animal model in preparation, it is characterized in that: described composition comprises the CLA mixture.
Wherein, content with respect to described composition, the weight fraction of described CLA mixture is preferably more than 0.1%, if parts by weight are lower than 0.1%, then can't obtain good diabetes animal model, because the CLA mixture does not have any infringement to animal, so weight fraction does not have the upper limit.
Wherein, described CLA (CLA) mixture is the mixture as the CLA monomer of isomer that a class contains conjugated double bond structures, mainly contain 9c, 11t-CLA, 10t, multiple CLA monomer such as 12c-CLA, therefore described CLA mixture can be 9c, 11t-CLA and 10t, any two or more mixture in the multiple CLA monomer such as 12c-CLA.
Wherein, further the CLA mixture in the preferred described composition is only by 9c, 11t-CLA and 10t, and two kinds of CLA monomers of 12c-CLA mix.
The present invention also provides a kind of composition to be used for making up the application of the feed or the medicine of type ii diabetes animal model in preparation, and described composition comprises 10t, 12c-CLA CLA monomer.
Wherein, content with respect to described composition, described 10t, the weight fraction of 12c-CLA CLA monomer is preferably more than 0.1%, if parts by weight are lower than 0.1%, then can't obtain good animal model, because 10t, 12c-CLA CLA monomer does not have any infringement to animal, so weight fraction does not have the upper limit.
Wherein, described 10t, 12c-CLA CLA monomer also can be by 9c, 11t-CLA CLA monomer etc. other arbitrarily the CLA monomer substitute.
Wherein, composition of the present invention is except comprising CLA mixture or single CLA monomer, also comprise other compositions arbitrarily, such as when preparation is used to make up the feed of type ii diabetes animal model, also add the conventional animal feed in the described composition, when preparation is used to make up the medicine of type ii diabetes animal model, in the described composition according to the different medicament of preparation, add auxiliary materials such as conventional solvent, adhesive, solubilizer, anticorrisive agent, make tablet, capsule, granule, oral liquid.
The present invention also provides a kind of feed or medicine that is used to make up the type ii diabetes animal model, and wherein, described feed or medicine comprise composition recited above.
The present invention also provides a kind of type ii diabetes animal model that obtains by above-mentioned feed of feeding or medicine, and it is characterized in that: described animal model has the feature of hyperglycaemia and hyperinsulinism, and has insulin resistance in the body.
The present invention also provides a kind of method for breeding of type ii diabetes animal model, it is characterized in that: give above-mentioned feed or medicine 4-6 week of feeding animal, obtain the type ii diabetes animal model.
By feed in the feeding animal technique scheme or medicine, can set up the type ii diabetes animal model of diet induced.
Wherein, described animal is preferably adopted mouse.
The present invention also provides a kind of preparation method of type ii diabetes animal model, and it may further comprise the steps: the first step, feed or medicine in the allotment technique scheme;
Second step is to the described feed or the medicine of feeding animal first step allotment.
Wherein, the feeding time in second step is preferably 4-6 week.
Wherein, the described animal in second step is preferably mouse.
The present invention also provides the application in making up the type ii diabetes animal model of the composition in the technique scheme, feed or medicine.
The present invention also provides the CLA mixture to be used for making up the application of feed or the medicine of type ii diabetes animal model in preparation.
The present invention also provides 10t, and 12c-CLA CLA monomer is used for making up the application of the feed or the medicine of type ii diabetes animal model in preparation.
The present invention is that derivant, mouse are the animal prototype with CLA mixture or single CLA monomer, and is cheap, conveniently is easy to get; The modeling time, the cycle was short in 4-6 week, and formed model is a feature with hyperglycaemia and hyperinsulinism, and has insulin resistance in the body, meets the type ii diabetes essential characteristic, is desirable type ii diabetes animal model.
Description of drawings
Fig. 1 is the evaluation map of the insulin resistance of embodiment of the invention animal model.
The specific embodiment
Below adopt embodiment to describe embodiments of the present invention in detail, how the application technology means solve technical problem to the present invention whereby, and the implementation procedure of reaching technique effect can fully understand and implements according to this.
Embodiment:
With commercially available mouse feed as normal control group mouse feed, in mouse feed, to add the 10t of 0.4wt%, 12c-CLA CLA monomer is as type ii diabetes modeling group mouse feed, the equal feed 6 all laggard end of line veins of freely ingesting of normal control group and type ii diabetes modeling group mouse are got blood, measure mouse fasting blood-glucose and insulin concentration, carry out sugared anti-experiment under the condition on an empty stomach simultaneously.All obviously rising and the anti-unusual mouse of sugar are the modeling success for fasting blood-glucose and insulin in the type ii diabetes modeling group.
In the present embodiment, described 10t, 12c-CLA CLA monomer is replaceable to be other CLA monomer or the CLA mixture of selecting two or more CLA monomers to form arbitrarily, commercially available mouse feed can change any other feeds that can satisfy mouse basic nutrition demand into, described mouse can be the mouse of any kind, all can obtain similar effects, set up the type ii diabetes animal model.
The model that the mouse type ii diabetes model that the present invention makes can be studied type ii diabetes cause and exploitation related drugs and health food composition uses.
Below CLA inducing mouse type ii diabetes model is further described:
One, the essential characteristic of CLA inducing mouse type ii diabetes model
Experimental results show that this model possesses the typical type ii diabetes feature of hyperglycaemia, hyperinsulinism.The C57BL/6J mouse is divided into 2 groups at random, and the 1st group is the normal control group; The 2nd group for containing 10t, the feed feeding group of 12c-CLA CLA monomer (type ii diabetes modeling group).The commercially available mouse powder feed of normal control group feeding, type ii diabetes modeling group feeding contains the 10t of 0.4wt%, and the commercially available mouse powder feed of 12c-CLA CLA monomer in 6 weeks of feeding, is measured mouse fasting blood-glucose and insulin level.The result shows, the normal control group of comparing mouse, and type ii diabetes modeling group mouse fasting blood-glucose has raise 0.76 times, and insulin level has raise 1.55 times, and glucose in urine detects and shows positive.Above result proves that the mouse type ii diabetes animal model modeling of inducing with CLA is successful.
The results are shown in Table 1.
Table 1 CLA to the influence of mouse fasting blood-glucose and insulin concentration (n=10,
)
Annotate:
△Compare with the normal control group expression P＜0.01;
N=10 represents that the number of every group of mouse is 10;
P is a significance probability, and P＜0.01 has utmost point significant difference between representing two groups.
Two, the insulin resistance feature of CLA inducing mouse type ii diabetes model
Experimental results show that this model possesses the characteristic feature of the peculiar insulin resistance of type ii diabetes.The C57BL/6J mouse is divided into 2 groups at random, and the 1st group is the normal control group; The 2nd group is CLA feeding group (type ii diabetes modeling group).The commercially available mouse powder feed of normal control group feeding, type ii diabetes modeling group feeding contains the 10t of 0.4wt%, the commercially available mouse powder feed of 12c-CLA CLA monomer, 6 weeks of feeding, mouse is jejunitas do not cut off the water supply 12 hours after, implement the experiment of insulin load.Found that type ii diabetes modeling group mouse significantly is lower than normal control group mouse to the insulin sensitivity degree, there is obvious insulin resistance in modeling group mouse, and this model possesses typical type ii diabetes Properties of Animal Models.The results are shown in Figure of description 1.
Comparative Examples: feeding contains the 10t of 0.05wt%, the essential characteristic of the inducing mouse type ii diabetes model of the feed of 12c-CLA CLA monomer
Experimental results show that this model does not possess the typical type ii diabetes feature of hyperglycaemia, hyperinsulinism.The C57BL/6J mouse is divided into 2 groups at random, and the 1st group is the normal control group; The 2nd group is CLA feeding group (type ii diabetes modeling group).The commercially available mouse powder feed of normal control group feeding, type ii diabetes modeling group feeding contains the 10t of 0.05wt%, and the commercially available mouse powder feed of 12c-CLA CLA monomer in 6 weeks of feeding, is measured mouse fasting blood-glucose and insulin level.The result shows, the normal control group of comparing mouse, and type ii diabetes modeling group mouse fasting blood-glucose and insulin all obviously do not raise, and glucose in urine detects and shows negative.Above result proves that to contain the 10t of 0.05wt%, the mouse type ii diabetes animal model modeling that the feed of 12c-CLA CLA monomer is induced is success not.
The results are shown in Table 2.
Table 2 CLA to the influence of mouse fasting blood-glucose and insulin concentration (n=10,
)
Annotate:
*Compare with the normal control group expression P＞0.05;
N=10 represents that the number of every group of mouse is 10;
P is a significance probability, and P＞0.05 does not have significant difference between representing two groups.
This intellectual property of primary enforcement that all are above-mentioned is not set restriction this new product of other forms of enforcement and/or new method.Those skilled in the art will utilize this important information, and foregoing is revised, to realize similar implementation status.But all modifications or transformation belong to the right of reservation based on new product of the present invention.
The above only is preferred embodiment of the present invention, is not to be the restriction of the present invention being made other form, and any those skilled in the art may utilize the technology contents of above-mentioned announcement to be changed or be modified as the equivalent embodiment of equivalent variations.But every technical solution of the present invention content that do not break away to any simple modification, equivalent variations and remodeling that above embodiment did, still belongs to the protection domain of technical solution of the present invention according to technical spirit of the present invention.
Claims (10)
1. a composition is used for making up the application of the feed or the medicine of type ii diabetes animal model in preparation, and it is characterized in that: described composition comprises the CLA mixture.
2. application as claimed in claim 1 is characterized in that: with respect to the content of described composition, the weight fraction of described CLA mixture is more than 0.1%.
3. a composition is used for making up the application of the feed or the medicine of type ii diabetes animal model in preparation, and it is characterized in that: described composition comprises 10t, 12c-CLA CLA monomer.
4. application as claimed in claim 3 is characterized in that: with respect to the content of described composition, and described 10t, the weight fraction of 12c-CLA CLA monomer is more than 0.1%.
5. a feed or medicine that makes up the type ii diabetes animal model, it is characterized in that: described feed or medicine comprise the described composition of claim 1 to 4.
6. type ii diabetes animal model that obtains by the described feed of feeding claim 5 or medicine, it is characterized in that: described animal model has hyperglycaemia and hyperinsulinism, has insulin resistance.
7. the method for breeding of an animal is characterized in that: give described feed of feeding animal claim 5 or medicine 4-6 week.
8. the preparation method of a type ii diabetes animal model is characterized in that: allotment described feed of claim 5 or medicine.
9. each described composition of claim 1 to 4 or the described feed of claim 5 or the medicine application in making up the type ii diabetes animal model.
10. CLA mixture or CLA monomer make up the feed of type ii diabetes animal model or the application in the medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100552130A CN102172261A (en) | 2011-03-09 | 2011-03-09 | Composition for constructing animal model of diabetes mellitus type II |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100552130A CN102172261A (en) | 2011-03-09 | 2011-03-09 | Composition for constructing animal model of diabetes mellitus type II |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102172261A true CN102172261A (en) | 2011-09-07 |
Family
ID=44515654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100552130A Pending CN102172261A (en) | 2011-03-09 | 2011-03-09 | Composition for constructing animal model of diabetes mellitus type II |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102172261A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103947876A (en) * | 2014-04-18 | 2014-07-30 | 兰州大学 | Feed for laboratory rats and mice and preparation method thereof |
| CN104970214A (en) * | 2015-08-13 | 2015-10-14 | 南京市溧水区人民医院 | Induction feed for establishment of type 2 diabetes mellitus animal model or obese animal model and application and application method of induction feed |
| CN106135133A (en) * | 2016-08-02 | 2016-11-23 | 四川大学 | The construction method of checking glucose resultant index animal experimental model and the animal model of structure thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579020A (en) * | 2009-06-24 | 2009-11-18 | 金国祥 | Edible oil without saturated fatty acid |
-
2011
- 2011-03-09 CN CN2011100552130A patent/CN102172261A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101579020A (en) * | 2009-06-24 | 2009-11-18 | 金国祥 | Edible oil without saturated fatty acid |
Non-Patent Citations (3)
| Title |
|---|
| 《中国粮油学报》 20090630 刘佩等 共轭亚油酸的生理学功能及健康意义 第24卷, 第6期 * |
| 《肠外与肠内营养》 20060331 徐文等 共轭亚油酸对糖尿病大鼠的治疗和控制作用 第13卷, 第2期 * |
| 《饲料工业》 20081231 邓其兰等 t10，c12-共轭亚油酸的生理效应及作用机制研究进展 第29卷, 第23期 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103947876A (en) * | 2014-04-18 | 2014-07-30 | 兰州大学 | Feed for laboratory rats and mice and preparation method thereof |
| CN104970214A (en) * | 2015-08-13 | 2015-10-14 | 南京市溧水区人民医院 | Induction feed for establishment of type 2 diabetes mellitus animal model or obese animal model and application and application method of induction feed |
| CN106135133A (en) * | 2016-08-02 | 2016-11-23 | 四川大学 | The construction method of checking glucose resultant index animal experimental model and the animal model of structure thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102757508B (en) | A kind of Radix Ophiopogonis polysaccharide extract has the application in the foodstuff additive of weight losing function, healthcare products or medicine in preparation | |
| CN102172261A (en) | Composition for constructing animal model of diabetes mellitus type II | |
| CN102894210A (en) | Anti-stress Chinese herbal medicine composite feedstuff additive specially used for penaeus vannamei | |
| CN106212858A (en) | A kind of high lipid food and animal model of diabetes mellitus type II | |
| CN205268724U (en) | Portable box for diabetes medicines | |
| CN104137992B (en) | A kind of hypoglycemia healthcare food and preparation method thereof | |
| CN103156865B (en) | L-arabinose is preparing the application in medicine or health product | |
| CN101797259B (en) | Compound vitamin nanoemulsion | |
| CN104664168A (en) | Multivitamin micro-emulsion preparation special for piglets, as well as preparation method and application of multivitamin micro-emulsion preparation | |
| CN102106467A (en) | Feed additive for reducing cholesterol content in eggs and preparation method thereof | |
| CN103860562B (en) | A kind of pharmaceutical composition and application thereof of setting up hyperuricemia animal model | |
| CN104758308A (en) | Traditional Chinese medicine oral liquid capable of improving immunity of livestock and poultry and preparation method thereof | |
| CN101559069A (en) | Application of 5' nucleotide in preparation of medicines and health-care foods for alleviating physical fatigue | |
| CN101406642B (en) | Antihypelipidemic compound formulation | |
| Morris et al. | A pilot study of a new chicken model of alcohol‐induced cardiomyopathy | |
| CN109997964A (en) | Purposes and corresponding feed of the gemma populi extract as feed addictive | |
| CN103621994B (en) | A kind of have food promoting digestive function and preparation method thereof | |
| Dessen et al. | Differences in fat accumulation between immature male and female Atlantic salmon Salmo salar after dietary administration of tetradecylthioacetic acid | |
| CN104825702A (en) | Composition capable of reducing fat and supplying nutrients and preparation method thereof | |
| CN115400126B (en) | Composition and medical application thereof | |
| CN108065102A (en) | A kind of broiler chicken feed additive | |
| CN108714181A (en) | A kind of Chinese medicine composition and its application in terms for the treatment of child's apositia | |
| CN102228477A (en) | Application of starfish extract to preparation of medicament for treating digestive system diseases | |
| CN108159435A (en) | A kind of citric acid resists mouse islets element the experimental method for the influence to be formed | |
| CN203001168U (en) | Bird infusion taking continuous injector |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110907 |